Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNTO 0007
- Development stage
- Phase 1
- Lead developer
- Janssen Research & Development
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CNTO 0007 is an investigational intravenously administered cell therapy developed by Janssen Research & Development (a Johnson & Johnson company) for neuroprotection and cell replacement. It is a stem cell therapy containing human umbilical tissue-derived cells (hUTC), designed to promote recovery after ischemic cerebral infarction (stroke). The drug was evaluated in Phase 1 clinical trials for its safety and tolerability in patients who had experienced ischemic stroke, but no further development has been reported since then. Its mechanism of action involves replacing damaged or lost neural cells to support functional recovery following neurological injury.
Beyond the preview
Go deeper on CNTO 0007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNTO 0007.